Bionpharma Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIONPHARMA INC, and what generic alternatives to BIONPHARMA INC drugs are available?
BIONPHARMA INC has forty-eight approved drugs.
There are five US patents protecting BIONPHARMA INC drugs.
There are ten patent family members on BIONPHARMA INC drugs in thirteen countries and seventy-four supplementary protection certificates in fourteen countries.
Summary for Bionpharma Inc
International Patents: | 10 |
US Patents: | 5 |
Tradenames: | 45 |
Ingredients: | 41 |
NDAs: | 48 |
Drug Master File Entries: | 2 |
Patent Litigation for Bionpharma Inc: | See patent lawsuits for Bionpharma Inc |
Drugs and US Patents for Bionpharma Inc
Expired US Patents for Bionpharma Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bionpharma Inc | MIDOL LIQUID GELS | ibuprofen | CAPSULE;ORAL | 021472-001 | Oct 18, 2002 | 6,251,426 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bionpharma Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1863458 | See Plans and Pricing |
Poland | 1863458 | See Plans and Pricing |
Mexico | 2007011039 | See Plans and Pricing |
China | 102940887 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2006096580 | See Plans and Pricing |
European Patent Office | 3061447 | See Plans and Pricing |
Canada | 2600023 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bionpharma Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0716606 | SPC/GB02/011 | United Kingdom | See Plans and Pricing | PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202 |
0914118 | SPC/GB07/002 | United Kingdom | See Plans and Pricing | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021. |
0716606 | C300428 | Netherlands | See Plans and Pricing | PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610 |
0245997 | C300002 | Netherlands | See Plans and Pricing | PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129 |
1441735 | 08C0026 | France | See Plans and Pricing | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
1441735 | 2008/010 | Ireland | See Plans and Pricing | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
0984957 | PA2011005,C0984957 | Lithuania | See Plans and Pricing | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.